8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 22, 2026·SEC
Shattuck Labs, Inc.(STTK)Earnings, Financials & Key Ratios
STTK•NASDAQ
$6.68
$422M mkt cap·Price updated May 6, 2026
AboutShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.Show more
- Revenue$6M+245.3%
- EBITDA-$77M+12.7%
- Net Income-$75M+13.6%
- EPS (Diluted)-1.49+27.3%
- Gross Margin100%+169.5%
- EBITDA Margin-1341.34%+74.7%
- Operating Margin-1408.27%+74.6%
- Net Margin-1318.13%+75.0%
- ROE-67.23%-23.6%
- ROIC-247.01%-181.1%
- Debt/Equity0.04+47.3%
STTK Key Insights
Shattuck Labs, Inc. (STTK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 10.4% over 5 years
- ✗Shares diluted 19.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
STTK Price & Volume
Shattuck Labs, Inc. (STTK) stock price & volume — 10-year historical chart
Loading chart...
STTK Growth Metrics
Shattuck Labs, Inc. (STTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-10.36%
3 Years-42.45%
TTM-84.46%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.33%
Return on Capital
10 Years-41.35%
5 Years-41.42%
3 Years-57.15%
Last Year-69.98%
STTK Recent Earnings
Shattuck Labs, Inc. (STTK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (89%)
Q2 2026Latest
Mar 5, 2026EPS
$0.12
Est $0.12
+0.0%
Revenue
—
Est $250,000
Q4 2025
Nov 6, 2025EPS
$0.14
Est $0.15
+6.7%
Revenue
$1M
Est $166,670
+500.0%
Q3 2025
Aug 14, 2025EPS
$0.24
Est $0.25
+4.0%
Revenue
—
Q2 2025
May 1, 2025EPS
$0.27
Est $0.29
+6.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.12vs $0.12+0.0% | —vs $250,000 |
| Q4 2025 | Nov 6, 2025 | $0.14vs $0.15+6.7% | $1Mvs $166,670+500.0% |
| Q3 2025 | Aug 14, 2025 | $0.24vs $0.25+4.0% | — |
| Q2 2025 | May 1, 2025 | $0.27vs $0.29+6.9% | — |
Based on last 12 quarters of dataView full earnings history →
STTK Peer Comparison
Shattuck Labs, Inc. (STTK) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 CRIS | 81.2M | 0.62 | -1.06 | -13.43% | -80.29% | -138.81% | 0.30 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare STTK vs Peers
Shattuck Labs, Inc. (STTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STTK Income Statement
Shattuck Labs, Inc. (STTK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 22.44M | 9.89M | 9.93M | 30.02M | 652K | 1.66M | 5.72M | 1M |
| Revenue Growth % | - | -55.94% | 0.48% | 202.16% | -97.83% | 154.14% | 245.26% | -84.46% |
| Cost of Goods Sold | 24.81M | 29.22M | 37.48M | 1.38M | 0 | 4.04M | 0 | 1.86M |
| COGS % of Revenue | 110.54% | 295.52% | 377.32% | 4.6% | - | 243.93% | - | - |
| Gross Profit | -2.37M▲ 0% | -19.33M▼ 717.4% | -27.55M▼ 42.5% | 28.64M▲ 203.9% | 652K▼ 97.7% | -2.38M▼ 465.8% | 5.72M▲ 339.9% | -865K▲ 0% |
| Gross Margin % | -10.54% | -195.52% | -277.32% | 95.4% | 100% | -143.93% | 100% | -86.5% |
| Gross Profit Growth % | - | -717.38% | -42.51% | 203.95% | -97.72% | -465.8% | 339.87% | - |
| Operating Expenses | 28.59M | 5.74M | 9.38M | 73.91M | 103.98M | 89.57M | 86.29M | 56.91M |
| OpEx % of Revenue | 127.4% | 58.02% | 94.44% | 246.21% | 15948.01% | 5405.67% | 1508.27% | - |
| Selling, General & Admin | 3.78M | 5.74M | 9.38M | 18.72M | 21.08M | 19.3M | 19.08M | 17.17M |
| SG&A % of Revenue | 16.86% | 58.02% | 94.44% | 62.37% | 3233.44% | 1165% | 333.46% | - |
| Research & Development | 24.81M | 29.22M | 37.48M | 56.56M | 82.9M | 74.31M | 67.21M | 41.61M |
| R&D % of Revenue | 110.54% | 295.52% | 377.32% | 188.44% | 12714.57% | 4484.61% | 1174.81% | - |
| Other Operating Expenses | -357K | -29.22M | -37.48M | -1.38M | 0 | -4.04M | 0 | -1.86M |
| Operating Income | -6.15M▲ 0% | -25.07M▼ 307.7% | -36.93M▼ 47.3% | -45.27M▼ 22.6% | -103.33M▼ 128.3% | -91.96M▲ 11.0% | -80.57M▲ 12.4% | -57.78M▲ 0% |
| Operating Margin % | -27.4% | -253.53% | -371.76% | -150.81% | -15848.01% | -5549.61% | -1408.27% | -5777.8% |
| Operating Income Growth % | - | -307.73% | -47.33% | -22.58% | -128.26% | 11.01% | 12.39% | - |
| EBITDA | -5.89M | -24.53M | -36.31M | -43.89M | -100.26M | -87.92M | -76.74M | -54.06M |
| EBITDA Margin % | -26.26% | -248.1% | -365.54% | -146.21% | -15376.69% | -5305.67% | -1341.34% | -5405.6% |
| EBITDA Growth % | - | -316.26% | -48.04% | -20.86% | -128.43% | 12.31% | 12.71% | 28.88% |
| D&A (Non-Cash Add-back) | 255K | 537K | 618K | 1.38M | 3.07M | 4.04M | 3.83M | 3.72M |
| EBIT | -4.76M | -25.07M | -36.93M | -45.27M | -103.33M | -91.96M | -80.57M | -56.54M |
| Net Interest Income | -1.67M | 1.18M | 549K | 625K | 1.59M | 4.67M | 5.17M | 5.17M |
| Interest Income | 966K | 1.18M | 549K | 625K | 1.59M | 4.67M | 5.17M | 5.17M |
| Interest Expense | 2.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.24M | 1.08M | 328K | 295K | 1.38M | 4.66M | 5.16M | 2.88M |
| Pretax Income | -7.39M▲ 0% | -23.98M▼ 224.6% | -36.6M▼ 52.6% | -44.97M▼ 22.9% | -101.94M▼ 126.7% | -87.3M▲ 14.4% | -75.41M▲ 13.6% | -54.9M▲ 0% |
| Pretax Margin % | -32.92% | -242.56% | -368.46% | -149.83% | -15635.74% | -5268.44% | -1318.13% | -5489.5% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.39M▲ 0% | -23.98M▼ 224.6% | -36.6M▼ 52.6% | -44.97M▼ 22.9% | -101.94M▼ 126.7% | -87.3M▲ 14.4% | -75.41M▲ 13.6% | -54.9M▲ 0% |
| Net Margin % | -32.92% | -242.56% | -368.46% | -149.83% | -15635.74% | -5268.44% | -1318.13% | -5489.5% |
| Net Income Growth % | - | -224.61% | -52.63% | -22.87% | -126.68% | 14.37% | 13.62% | 26.23% |
| Net Income (Continuing) | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M | -54.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.49▲ 0% | -0.57▼ 16.3% | -0.88▼ 54.4% | -1.07▼ 21.6% | -2.41▼ 125.2% | -2.05▲ 14.9% | -1.49▲ 27.3% | -0.76▲ 0% |
| EPS Growth % | - | -16.33% | -54.39% | -21.59% | -125.23% | 14.94% | 27.32% | 33.33% |
| EPS (Basic) | -0.49 | -0.57 | -0.88 | -1.07 | -2.41 | -2.05 | -1.49 | - |
| Diluted Shares Outstanding | 15.04M | 41.74M | 41.77M | 42.03M | 42.38M | 42.6M | 50.76M | 72.18M |
| Basic Shares Outstanding | 15.04M | 41.74M | 41.77M | 42.03M | 42.38M | 42.6M | 50.76M | 72.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
STTK Balance Sheet
Shattuck Labs, Inc. (STTK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.63M | 42.44M | 345.64M | 288.27M | 184.58M | 143.22M | 79.22M | 90.72M |
| Cash & Short-Term Investments | 60.38M | 39.09M | 335.45M | 268.8M | 161.28M | 130.63M | 72.99M | 42.55M |
| Cash Only | 31.64M | 7.01M | 157.9M | 92.27M | 47.38M | 125.63M | 57.39M | 42.55M |
| Short-Term Investments | 28.73M | 32.07M | 177.55M | 176.54M | 113.9M | 5M | 15.6M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 23.3M | 12.6M | 6.23M | 48.17M |
| Total Non-Current Assets | 2.53M | 2.53M | 3.35M | 10.32M | 20.74M | 16.34M | 11.83M | 9.61M |
| Property, Plant & Equipment | 2.5M | 2.44M | 3M | 9.94M | 17.67M | 13.8M | 9.81M | 7.05M |
| Fixed Asset Turnover | 8.96x | 4.06x | 3.31x | 3.02x | 0.04x | 0.12x | 0.58x | 0.12x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 23K | 90K | 349K | 381K | 3.07M | 2.54M | 2.02M | 8.22M |
| Total Assets | 68.16M▲ 0% | 44.97M▼ 34.0% | 348.99M▲ 676.1% | 298.58M▼ 14.4% | 205.32M▼ 31.2% | 159.56M▼ 22.3% | 91.05M▼ 42.9% | 100.33M▲ 0% |
| Asset Turnover | 0.33x | 0.22x | 0.03x | 0.10x | 0.00x | 0.01x | 0.06x | 0.01x |
| Asset Growth % | - | -34.03% | 676.06% | -14.44% | -31.23% | -22.29% | -42.94% | -150.35% |
| Total Current Liabilities | 20.85M | 19.98M | 16.83M | 24.59M | 24.96M | 11.45M | 8.92M | 5.34M |
| Accounts Payable | 2.05M | 3.05M | 1.75M | 10.01M | 7.17M | 1.59M | 2.42M | 1.16M |
| Days Payables Outstanding | 30.13 | 38.11 | 17.08 | 2.65K | - | 143.31 | - | 273.46 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 17.04M | 12.89M | 7.73M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 983K | 3.07M | 5.8M | 11.25M | 5.84M | 4.83M | 5.6M | 4.17M |
| Current Ratio | 3.15x | 2.12x | 20.53x | 11.72x | 7.39x | 12.51x | 8.88x | 8.88x |
| Quick Ratio | 3.15x | 2.12x | 20.53x | 11.72x | 7.39x | 12.51x | 8.88x | 8.88x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 58.39M | 59.53M | 22.29M | 2.21M | 4.2M | 3.41M | 2.51M | 1.76M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.76M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 4.2M | 3.41M | 2.51M | 6.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 50M | 49.96M | 987K | 2.21M | 0 | 0 | 0 | 0 |
| Total Liabilities | 79.24M | 79.52M | 39.13M | 26.8M | 29.17M | 14.86M | 11.42M | 7.09M |
| Total Debt | 0 | 0 | 0 | 0 | 4.9M | 4.2M | 3.41M | 1.76M |
| Net Debt | -31.64M | -7.01M | -157.9M | -92.27M | -42.48M | -121.42M | -53.98M | -40.79M |
| Debt / Equity | - | - | - | - | 0.03x | 0.03x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.75x |
| Interest Coverage | -2.34x | - | - | - | - | - | - | - |
| Total Equity | -11.08M▲ 0% | -34.55M▼ 211.8% | 309.86M▲ 996.9% | 271.79M▼ 12.3% | 176.16M▼ 35.2% | 144.71M▼ 17.9% | 79.63M▼ 45.0% | 93.24M▲ 0% |
| Equity Growth % | - | -211.78% | 996.9% | -12.29% | -35.19% | -17.85% | -44.97% | -144.41% |
| Book Value per Share | -0.74 | -0.83 | 7.42 | 6.47 | 4.16 | 3.40 | 1.57 | 1.29 |
| Total Shareholders' Equity | -11.08M | -34.55M | 309.86M | 271.79M | 176.16M | 144.71M | 79.63M | 93.24M |
| Common Stock | 1K | 1K | 5K | 5K | 5K | 5K | 5K | 7K |
| Retained Earnings | -11.51M | -35.49M | -72.09M | -117.07M | -219.01M | -306.31M | -381.72M | -417.94M |
| Treasury Stock | 0 | -887K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -49.06M | 54K | -63K | -560K | -877K | 4K | 2K | 3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STTK Cash Flow Statement
Shattuck Labs, Inc. (STTK) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.9M | -20.98M | -33.66M | -57.12M | -94.5M | -81.23M | -60.52M | -60.52M |
| Operating CF Margin % | -30.76% | -212.15% | -338.83% | -190.28% | -14493.56% | -4902.11% | -1057.77% | - |
| Operating CF Growth % | - | -203.85% | -60.47% | -69.69% | -65.45% | 14.04% | 25.5% | 84.98% |
| Net Income | -7.39M | -23.98M | -36.6M | -44.97M | -101.94M | -87.3M | -75.41M | -54.9M |
| Depreciation & Amortization | 255K | 537K | 618K | 1.38M | 3.07M | 4.04M | 3.83M | 3.72M |
| Stock-Based Compensation | 425K | 461K | 1.27M | 5.47M | 6.46M | 6.94M | 9.55M | 5.46M |
| Deferred Taxes | -404K | 0 | 1K | 3.04M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.71M | -207K | 89K | 1.52M | 2.38M | -816K | -1.5M | 1.38M |
| Working Capital Changes | -2.5M | 2.22M | 970K | -23.55M | -4.46M | -4.09M | 3.02M | -4.43M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.12M | 1M | -1.75M | 7.87M | -2.84M | -5.63M | 832K | -2.45M |
| Cash from Investing | -29.93M | -3.59M | -146.32M | -10.44M | 49.44M | 110.86M | -8.51M | 3.11M |
| Capital Expenditures | -1.18M | -470K | -727K | -7.93M | -11.61M | -407K | -59K | -71K |
| CapEx % of Revenue | 5.25% | 4.75% | 7.32% | 26.41% | 1781.29% | 24.56% | 1.03% | - |
| Acquisitions | 0 | 0 | 145.59M | 2.52M | 104K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -15K | 0 | -145.59M | -2.52M | 0 | 0 | 0 | -43.42M |
| Cash from Financing | 35.15M | -64K | 330.87M | 1.93M | 171K | 48.62M | 787K | 44.37M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 171K | 1000K | -17K | -64K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -152K | -64K | -19.05M | 0 | 0 | -53K | 804K | 44.43M |
| Net Change in Cash | -1.68M▲ 0% | -24.63M▼ 1363.5% | 150.88M▲ 712.6% | -65.63M▼ 143.5% | -44.89M▲ 31.6% | 78.25M▲ 274.3% | -68.24M▼ 187.2% | -1.28M▲ 0% |
| Free Cash Flow | -8.08M▲ 0% | -21.45M▼ 165.4% | -34.39M▼ 60.3% | -65.04M▼ 89.2% | -106.11M▼ 63.1% | -81.64M▲ 23.1% | -60.57M▲ 25.8% | -48.83M▲ 0% |
| FCF Margin % | -36.01% | -216.9% | -346.14% | -216.68% | -16274.85% | -4926.67% | -1058.8% | -4883.3% |
| FCF Growth % | - | -165.38% | -60.35% | -89.15% | -63.14% | 23.07% | 25.8% | 22.04% |
| FCF per Share | -0.54 | -0.51 | -0.82 | -1.55 | -2.50 | -1.92 | -1.19 | -1.19 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.87x | 0.92x | 1.27x | 0.93x | 0.93x | 0.80x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
STTK Key Ratios
Shattuck Labs, Inc. (STTK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -26.59% | -15.46% | -45.52% | -54.41% | -67.23% | -58.87% |
| Return on Invested Capital (ROIC) | - | -50.18% | -20.48% | -49.49% | -87.88% | -247.01% | -247.01% |
| Gross Margin | -195.52% | -277.32% | 95.4% | 100% | -143.93% | 100% | -86.5% |
| Net Margin | -242.56% | -368.46% | -149.83% | -15635.74% | -5268.44% | -1318.13% | -5489.5% |
| Debt / Equity | - | - | - | 0.03x | 0.03x | 0.04x | 0.04x |
| FCF Conversion | 0.87x | 0.92x | 1.27x | 0.93x | 0.93x | 0.80x | 0.89x |
| Revenue Growth | -55.94% | 0.48% | 202.16% | -97.83% | 154.14% | 245.26% | -84.46% |
STTK SEC Filings & Documents
Shattuck Labs, Inc. (STTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
STTK Frequently Asked Questions
Shattuck Labs, Inc. (STTK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue for fiscal year 2024. This represents a 96% decrease from $22.4M in 2018.
Shattuck Labs, Inc. (STTK) grew revenue by 245.3% over the past year. This is strong growth.
Shattuck Labs, Inc. (STTK) reported a net loss of $54.9M for fiscal year 2024.
Dividend & Returns
Shattuck Labs, Inc. (STTK) has a return on equity (ROE) of -67.2%. Negative ROE indicates the company is unprofitable.
Shattuck Labs, Inc. (STTK) had negative free cash flow of $48.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More STTK
Shattuck Labs, Inc. (STTK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates